MarketCap
Facebook
X
TelegramAnnual report 2024
added 02-27-2025
ACADIA Pharmaceuticals Book Value 2011-2026 | ACAD
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value ACADIA Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 733 M | 432 M | - | 541 M | 627 M | 699 M | 479 M | 335 M | 518 M | 200 M | 309 M | 182 M | 85 M | 23.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 733 M | 23.4 M | 397 M |
Quarterly Book Value ACADIA Pharmaceuticals
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 374 M | 400 M | - | 435 M | 445 M | 541 M | 567 M | 565 M | 582 M | 627 M | 627 M | 627 M | 627 M | 699 M | 699 M | 699 M | 699 M | 479 M | 479 M | 479 M | 479 M | 335 M | 335 M | 335 M | 335 M | 518 M | 518 M | 518 M | 518 M | 200 M | 200 M | 200 M | 200 M | 309 M | 309 M | 309 M | 309 M | 182 M | 182 M | 182 M | 182 M | 103 M | 103 M | 99.4 M | 99.7 M | 23.4 M | 23.4 M | 23.4 M | 23.4 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 699 M | 23.4 M | 371 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
282 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
8.32 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
35.5 M | $ 3.8 | 5.33 % | $ 9.14 B |  Australia |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
124 M | $ 2.63 | -1.22 % | $ 16.5 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
13.2 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
19.2 B | $ 88.34 | -3.22 % | $ 27.2 B | Germany |
 |
Akari Therapeutics, Plc
AKTX
|
28.3 M | $ 3.41 | -3.67 % | $ 230 B | Britain |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
169 M | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
789 M | $ 316.2 | -4.28 % | $ 41.4 B | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
78.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Burford Capital Limited
BUR
|
1.66 B | $ 4.44 | -0.67 % | $ 730 M | Britain |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
3.36 M | - | -11.43 % | $ 502 K | USA |
 |
argenx SE
ARGX
|
7.32 B | $ 743.15 | -0.68 % | $ 25 B |  Niderland |
 |
Завод ДИОД
DIOD
|
-243 M | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
29.8 B | - | - | - | Russia |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Aptorum Group Limited
APM
|
11.8 M | $ 0.89 | - | $ 4.85 M | China |
 |
Applied Therapeutics
APLT
|
-17.1 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
Teligent, Inc.
TLGT
|
5.17 B | - | -13.85 % | $ 16.1 M | USA |
 |
Cerus Corporation
CERS
|
65 M | $ 1.8 | -2.7 % | $ 343 M | USA |
 |
AbbVie
ABBV
|
134 B | $ 202.28 | -2.11 % | $ 358 B | USA |
 |
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.04 | -1.28 % | $ 432 M | USA |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Viela Bio, Inc.
VIE
|
424 M | - | - | $ 2.91 B | USA |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.63 | -2.69 % | $ 191 M | USA |
 |
AbCellera Biologics
ABCL
|
967 M | $ 3.32 | -2.06 % | $ 992 M | Canada |
 |
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 8.12 | -1.22 % | $ 222 M |  Israel |
 |
Ardelyx
ARDX
|
167 M | $ 5.8 | -2.93 % | $ 1.4 B | USA |